Please assess the completion status of the following clinical trial:

Trial Title: Hydroxytyrosol and Vitamin E in Pediatric NASH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Liver biopsy consistent with diagnosis of NASH (liver biopsy performed in 3-6 months before enrollment)~* Hyperechogenicity of liver at ultrasound examination~* ALT levels range between normal and \< 10 UNL~* INR \< 1.3~* Albumin \> 3 gr/dl.~* Total bilirubin \< 2.5 mg/dl~* normal renal function~* normal cells blood count~* exclusion of other causes of chronic hepatopathies in children~* Written informed consent to participate in the Protocol by their parents or legal guardians of patients~Exclusion Criteria:~* alcohols or drugs abuse~* use of drugs known to induce steatosis or to affect body weight or carbohydrate metabolism~* autoimmune liver diseases, Wilson's disease, alpha-1-antitripsin deficiency, metabolic liver disease~* every clinical or psychiatric diseases interfering with experimentation according to investigator's evaluation~* finding of active liver disease due to other causes

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- TREATED GROUP (Type: EXPERIMENTAL): This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks.
- PLACEBO GROUP (Type: PLACEBO_COMPARATOR): This group will treated with 2 identical placebo pills daily given orally for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).